In April 2020, the article 'Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY1161909 and BAY1217389, Targeting MPS1 Kinase' ( describing two inhibitors of monopolar spindle 1 (MPS1) kinase with interesting anti-cancer mechanism was published. Instead of stopping cancer cell growth, cells are driven into mitosis, resulting in cell death due to a high degree of chromosomal disaggregation. One of clinical candidates (BAY1161909) contains substituted [1,2,4]triazolo[1,5-a]pyridin moiety in its backbone. We have made a set of compounds, which contain such moiety – the perfect start for your research!